The List of Prohibited Substances and Methods (the List), an International Standard published yearly by the World Anti-Doping Agency (WADA), determines which substances and methods are prohibited in sport in-and out-of-competition. Stimulants are included within drug class S.6 under the in-competition testing section of the List. Athletes may be tempted to use stimulants as ergogenic aids in-competition in order to temporarily improve their mental and/or physical functions by increasing alertness, aggressiveness, motivation, locomotion, heart rate, and reducing fatigue. The Prohibited List Expert Group, responsible for the maintenance of the List, approved WADA funding for a two-year study to determine whether athletes were also using stimulants to benefit from their performance-enhancing effects during the training phase between competitions (i.e., out-of-competition). This study, involving 11 WADA-accredited laboratories, found that the use of stimulants by athletes during training was not significantly prevalent (0.36% of positive findings), suggesting that this issue does not, at the moment, pose a further challenge to the fight against doping in sport. In addition, the study supports the current structure in the Prohibited List that differentiates banned substances into the in-and out-of-competition classifications.
Introduction
The use of stimulants is prohibited in sports in-competition. As indicated in the World Anti-Doping Code (1), substances prohibited in-competition are not considered to have the potential to enhance performance in future sports events, and therefore, there is no need to ban them at all times. Nevertheless, following the publication of the 2004 List of Prohibited and Substances and Methods (the List) (2) , the first to be published by WADA, some stakeholders proposed amending the List into a single set of prohibited substances prohibited at all times. As a consequence, the List would not distinguish whether drugs are used in-or out-of-competition. In view of these comments, the issue of stimulant use by athletes during the out-of-competition period was first considered by the WADA Prohibited List Expert Group (3) in 2005. Because very limited data existed on this subject, the List Expert Group decided to investigate this possibility and established a monitoring program (OOC Stimulant Program) to detect patterns of misuse of stimulants in athlete samples collected out-ofcompetition (OOC).
Eleven WADA-accredited laboratories were selected to participate in the study, with consideration given based on factors such as geographic location and access to samples from national and international-level athletes from various sports. Three laboratories pooled their resources to meet the 1000 sample requirement, and eight agreed to provide at least 1000 samples. The laboratories were requested to analyze routine OOC samples that were to be received that year within their normal testing schedule. Therefore, in 2006, at least 9000 samples were expected to be analyzed for the purposes of this study. Because the analysis of stimulants would require additional tests outside the usual OOC testing menu, WADA made funding available to the participating laboratories to cover the additional costs involved.
The OOC Stimulant Program was documented in the WADA Monitoring Program description that was provided to each participating laboratory and published on WADA's website (4). The 2006 and 2007 OOC Stimulant Programs included the following non-specified stimulants: adrafinil, adrenaline, amfepramone, amiphenazole, amphetamine, amphetaminil, benzphetamine, benzylpiperazine, bromantan, clobenzorex, cocaine, cyclazodone, dimethylamphetamine, etilamphetamine, etilefrine, fenbutrazate, fencamfamin, fencamine, fenetylline, fenfluramine, fenoroporex, furfenorex, mefenorex, mephentermine, mesocarb, methamphetamine (d-), methylenedioxyamphetamine, methylenedioxymethamphetamine, methylphenidate, modafinil, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phenmetrazine, phentermine, 4-phenylpiracetam (Carphedon), prolintane, and strychnine.
Under the 2003 World Anti-Doping Code, specified substances were defined as those that could cause unintentional anti-doping rule violations because of their general availability in medicinal products or because they were less likely to be successfully abused as doping agents. The 2006 and 2007 Prohibited Lists clarified stimulants from drug class S.6 that were considered as "specified". The OOC testing menu of non-specified stimulants therefore represented stimulants that are likely taken with the intent to enhance performance.
The laboratories were requested to apply their standard initial testing procedure for the detection of stimulants as an additional test of the OOC samples. The standard initial testing procedure for stimulants is required to meet the 500 ng/mL Minimum Required Performance Limit (MRPL) as stipulated by the WADA MRPL Technical Document in force at the time. One exception is strychnine with a MRPL of 200 ng/mL. This analysis was conducted after the standard OOC testing menu had declared the samples negative and had shown no further testing needs.
By the end of 2006, the results were reported to WADA anonymously, that is, without any reference to identifying information. The reported results included sport, gender, and the substance(s) identified.
Results

monitoring program
Most laboratories were able to provide data on more samples than required, which resulted in over 14,000 samples analyzed including 84 different sports in all. A total of 49 stimulants were detected, representing a 0.34% rate of detection (Table I ). The detection of cocaine metabolite(s) accounted for nearly half of the stimulants detected (Table II) . In addition, several cases involved the detection of more than one stimulant. In most cases, the stimulants reported included drugs that could fall under recreational or medicinal (e.g., ADHD treatment) use. Nearly half the total number of analyzed samples was attributed to 5 sports, namely, aquatics, athletics, cycling, skiing, and weightlifting, with at least 1 stimulant finding identified in 18 different sports (Table III) . In most sports, the percentage of findings was around 1% or lower (Table III) . The highest percentages of findings were found in sports where the number of tests was the lowest, suggesting a bias due to the limited number of samples available (Table III) .
Although the overall 2006 results suggested an absence of systematic doping with stimulants during the out-ofcompetition phase, some data were considered suspicious because of unusual patterns of occurrences in some particular sports and countries, and therefore, the List Expert Group found the results interesting enough to approve an extension of the study for an additional year. In addition, by doing so, more samples could be analyzed, and the statistical power of the study would be increased. 
Monitoring program
By the end of 2007, the results once again were reported to WADA anonymously, meaning without any reference to identifying information. As in 2006, the reported results included sport, gender and substance identified.
The laboratories provided results on over 10,000 OOC samples corresponding to 64 different sports. A total of 41 stimulants were detected representing a 0.39% rate of detection (Table IV ). The detection of cocaine metabolite(s) again accounted for most of the stimulant findings and represented 37% of the stimulants detected (Table V) . In addition, several cases involved the detection of more than one stimulant. As in the previous year, most cases reported involved drugs that could fall under recreational or medicinal (e.g., ADHD treatment) use. Nearly half the total number of analyzed samples was attributed to three sports, namely aquatics, athletics, and cycling, with at least 1 stimulant finding identified in 12 different sports (Table VI) . The highest percentage of findings corresponded to the sports with lower number of tests, suggesting again a bias due to the small sample size or specific programs targeting athletes, which raises the likelihood of detecting doping practices.
The Prohibited List Expert Group also noted that Laboratory 1 reported a significantly higher percentage of findings during both phases of the study. Although a conclusive basis for this phenomenon was unknown, the discussion noted anecdotal evidence that this country may have a particular social issue with "recreational" drug use.
The 2007 results did not change the initial observations of the Prohibited List Expert Group and further supported the conclusion of the 2006 data pointing to an absence of systematic abuse of stimulants for the purpose of enhancing performance during the out-of-competition phase by athletes.
Conclusions
As a result of the collaborative effort between WADA and participating WADA-accredited laboratories, more than 25,000 anti-doping samples collected out-of-competition and representing 89 different sports in total were analyzed for stimulants normally included in the test menu reserved for samples col- Reports are considered underestimations due to the inability to extract the number of in-competition tests (from which the stimulants findings were reported) from the total number of tests reported.
However, if we were to use these data as guidance for comparison with the overall 0.36% rate in the OOC Stimulant Program, then there would not seem to be overwhelming support to suggest that athletes abuse stimulants during the training phases for the purposes of enhancing performance during the training phase between competitions. The prevalence of "recreational" drugs among the OOC Stimulant program analytical findings suggests a recreational, rather than doping, use of stimulants during out-of-competition periods. The results of this study support the differentiation of prohibited substances between in-and out-of-competition in the List of Prohibited Substances and Methods.
